Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Title: Developing a novel drug for neurobehavioral deficits in FASD

Award Number: R42AA029025
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Title: Developing a novel drug for neurobehavioral deficits in FASD - Summary Fetal Alcohol Spectrum Disorders (FASD) represent a range of lifelong cognitive, behavioral, and physical impairments caused by prenatal alcohol exposure (PAE). The estimated prevalence of FASD is 2.0-5.0% in the U.S. and Western Europe, causing substantial treatment costs. Currently available medications for FASD are essentially limited to the management of ADHD and anxiety, and there is a strong need for new medications to target other broader issues in FASD patients. Cogthera LLC aims to develop a drug to address cognitive and learning difficulties in FASD by targeting a novel mechanism mediated by the KCNN2 channel that we discovered to be affected by PAE. The patent for the use of peptide compounds targeting this mechanism is held by Children's National Hospital (CNH). These compounds have shown improvements of behavioral issues in a mouse model of FASD via intranasal application. Building upon the successful selection of the top candidate peptide FA-1 through initial efficacy and safety testing in the STTR Phase I study, this Phase II study focuses on the following objectives: Produce GLP-grade FA-1 and comprehensively characterize its drug-like properties, bioactivity, pharmacokinetics (PK), pharmacodynamics (PD), and safety in vitro (Aim 1); Optimize FA-1's formulation for intranasal administration, evaluate its efficacy in FASD animal models of acute and chronic maternal alcohol drinking, and obtain regulatory feedback through an INTERACT meeting with FDA to guide subsequent in vivo studies (Aim 2); Conduct single- dose and multiple-dose PK studies as well as toxicity and safety assessments of FA-1 in both rodent (mouse) and non-rodent (rabbit) models (Aim 3). These studies will generate critical preclinical data to establish safe and effective dosing regimens, thereby supporting regulatory approval and facilitating IND submission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = $0 )
2027	2026	COGTHERA LLC	20500 RIGGS HILL WAY	BROOKEVILLE	MD	20833	MONTGOMERY	USA	Alcohol Research Programs	000	3	10/20/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2026 ( Subtotal = $1,008,965 )
2026	2026	COGTHERA LLC	20500 RIGGS HILL WAY	BROOKEVILLE	MD	20833	MONTGOMERY	USA	Alcohol Research Programs	001	3	8/13/2026	NON-COMPETING CONTINUATION	$1,008,965
2026	2025	COGTHERA LLC	20500 RIGGS HILL WAY	BROOKEVILLE	MD	20833	MONTGOMERY	USA	Alcohol Research Programs	000	2	7/14/2026	COMPETING CONTINUATION	$0
														Subtotal = $1,008,965

Issue Date FY: 2025 ( Subtotal = $1,077,312 )
2025	2025	COGTHERA LLC	20500 RIGGS HILL WAY	BROOKEVILLE	MD	20833	MONTGOMERY	USA	Alcohol Research Programs	000	2	9/18/2025	COMPETING CONTINUATION	$1,077,312
														Subtotal = $1,077,312

Grand Total All Awards = $2,086,277

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Title: Developing a novel drug for neurobehavioral deficits in FASD

Award Number: R42AA029025

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer